Cerdulatinib

未知生产厂商

Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)).

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)).

技术标识符

化学式: C₂₀H₂₇N₇O₃S
CAS 编号: 1198300-79-6
UNII ID: D1LXQ45S1O

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

Methods for treating lymphoma
US 11266645 B2申请人: ALEXION PHARMA INC优先权: 2018
CN
US
3 件公开
Cerdulatinib for the treatment of b-cell malignancies
US 12350269 B2申请人: ALEXION PHARMA INC优先权: 2015
CN
US
2 件公开
Cerdulatinib for treating myeloma
US 12150942 B2申请人: ALEXION PHARMA INC优先权: 2015
CN
US
2 件公开
PHARMACEUTICAL COMPOSITION, ORGAN PRESERVATION SOLUTION, AND USE THEREOF
WO 2025162212 A1申请人: THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIV优先权: 2024
CN
WO
2 件公开
Cerdulatinib for treating hematological cancers
US 10736895 B2申请人: PORTOLA PHARM INC优先权: 2016
US
2 件公开
Solid forms of cerdulatinib
US 10865198 B2申请人: PORTOLA PHARM INC优先权: 2019
US
2 件公开
Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
CN 111818910 A申请人: DERMAVANT SCIENCES GMBH优先权: 2018
CN
Synthesis of cerdulatinib
US 11339145 B2申请人: ALEXION PHARMA INC优先权: 2020
US
CIRCULATING B CELL SUBPOPULATIONS IN INDOLENT B CELL LYMPHOMA
US 2023181581 A1申请人: ALEXION PHARMA INC优先权: 2021
US

药物